U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2000
171
Name Type Language
GEMTUZUMAB OZOGAMICIN
EMA EPAR   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
GEMTUZUMAB OZOGAMICIN [USAN]
Common Name English
GEMTUZUMAB OZOGAMICIN [MI]
Common Name English
CMC-676
Code English
GEMTUZUMAB OZOGAMICIN [JAN]
Common Name English
CMA-676
Code English
GEMTUZUMAB OZOGAMICIN [VANDF]
Common Name English
Gemtuzumab ozogamicin [WHO-DD]
Common Name English
MYLOTARG
Brand Name English
GEMTUZUMAB OZOGAMICIN RECOMBINANT
Common Name English
GEMTUZUMAB OZOGAMICIN [EMA EPAR]
Common Name English
GEMTUZUMAB OZOGAMICIN [ORANGE BOOK]
Common Name English
WAY-CMA-676
Code English
GEMTUZUMAB OZOGAMICIN [MART.]
Common Name English
GEMTUZUMAB OZOGAMICIN (GENETICAL RECOMBINATION) [JAN]
JAN  
Common Name English
gemtuzumab ozogamicin [INN]
Common Name English
GEMTUZUMAB OZOGAMICIN [PURPLE BOOK CDER]
Common Name English
CDP-771
Code English
L01XC05
Code English
Classification Tree Code System Code
EU-Orphan Drug EU/3/00/005
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
NDF-RT N0000175571
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
NCI_THESAURUS C129823
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
WHO-ATC L01XC05
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
EMA ASSESSMENT REPORTS MYLOTARG (REFUSED: LEUKEMIA, MYELOID, ACUTE)
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
NCI_THESAURUS C2333
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
LIVERTOX NBK548438
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
FDA ORPHAN DRUG 127899
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
Code System Code Type Description
MERCK INDEX
m5694
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL1201506
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
PRIMARY
RXCUI
1294580
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
PRIMARY RxNorm
CAS
220578-59-6
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
PRIMARY
SMS_ID
100000089560
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
PRIMARY
WIKIPEDIA
Gemtuzumab ozogamicin
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
PRIMARY
LACTMED
Gemtuzumab Ozogamicin
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
PRIMARY
EVMPD
SUB20794
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
PRIMARY
DAILYMED
8GZG754X6M
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
PRIMARY
IUPHAR
6775
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
PRIMARY
NCI_THESAURUS
C1806
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
PRIMARY
FDA UNII
8GZG754X6M
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
PRIMARY
DRUG CENTRAL
4980
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
PRIMARY
DRUG BANK
DB00056
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
PRIMARY
INN
10315
Created by admin on Sat Dec 16 16:45:19 GMT 2023 , Edited by admin on Sat Dec 16 16:45:19 GMT 2023
PRIMARY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966